K
KalVista Pharmaceuticals D
D
KALV
19.840
USD
-1.04
(-4.98%)
مفتوح الان
حجم التداول
13,263
الربح لكل سهم
-1
العائد الربحي
-
P/E
-5
حجم السوق
1,017,790,817
العنوان: KalVista Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.